Orange Book product · Brand (NDA)
EMEND
FOSAPREPITANT DIMEGLUMINE
At a glance
Nov 12, 2010
Approved
Brand (NDA)
Application
AP
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Nov 12, 2010
15 yr 10 mo ago
Today
Pharmaceutical detail
Active ingredient
FOSAPREPITANT DIMEGLUMINE
Strength
EQ 150MG BASE/VIAL
Dosage form
POWDER
Route
INTRAVENOUS
TE code
AP
Application
NDA 022023
Product number
002
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2023FOCINVEZBrand (NDA)
NDA 216686 · STERISCIENCE
- 2019FOSAPREPITANT DIMEGLUMINEBrand (NDA)
NDA 210064 · TEVA PHARMS USA
- 2023FOSAPREPITANT DIMEGLUMINEGeneric (ANDA)
ANDA 214683 · PIRAMAL CRITICAL
- 2021FOSAPREPITANT DIMEGLUMINEGeneric (ANDA)
ANDA 213199 · PRAXGEN
- 2021FOSAPREPITANT DIMEGLUMINEGeneric (ANDA)
ANDA 214616 · ASPIRO
- 2021FOSAPREPITANT DIMEGLUMINEGeneric (ANDA)
ANDA 212143 · CHIA TAI TIANQING
- 2021FOSAPREPITANT DIMEGLUMINEGeneric (ANDA)
ANDA 210625 · EUGIA PHARMA
- 2020FOSAPREPITANT DIMEGLUMINEGeneric (ANDA)
ANDA 211160 · DR REDDYS
- 2020FOSAPREPITANT DIMEGLUMINEGeneric (ANDA)
ANDA 203939 · CAPLIN
- 2020FOSAPREPITANT DIMEGLUMINEGeneric (ANDA)
ANDA 213106 · QILU PHARM HAINAN
- 2020FOSAPREPITANT DIMEGLUMINEGeneric (ANDA)
ANDA 204025 · ACCORD HLTHCARE
- 2020FOSAPREPITANT DIMEGLUMINEGeneric (ANDA)
ANDA 212957 · NAVINTA LLC
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
